Medical Professionals
Medical healthcare providers can find more information and tools here to support patient care and research into innovative medicines.
We believe in the power of science in addressing some of the most challenging diseases of our time. Along with our long history of developing life-saving medicines, we have a promising pipeline that will shape the next generation of treatment options across various indications in four therapeutic areas.
Bristol Myers Squibb is active in four therapeutic areas
Oncology
Bristol Myers Squibb (BMS) is a leader in the field of oncology, with a comprehensive portfolio of both approved and investigational medicines.
Our focus lies in four key areas:
- Through our focus on tumour biology and translational research, we identify the right treatments for suitable patients at the right time.
- We are exploring new therapies that have the potential to change existing standards of care.
- We are exploring opportunities for patients who cannot currently be treated using checkpoint inhibitors.
- In IO-responsive tumours, we try to increase, deepen, and/or prolong the body's natural response to recognise and destroy cancer cells.
Immunology
The ImmunoScience Academy website is an online platform that provides information and educational material for physicians.
It is led by a steering committee of professors and experts from various therapeutic areas. Their mission is to educate and stimulate multidisciplinary initiatives within the field of ImmunoScience to optimise patient care.
Hematology
Hematology is a fundamental pillar of Bristol Myers Squibb in which we have made significant progress.
We are determined to maintain our leading role and expertise in developing breakthrough therapies to treat patients with malignant and benign hematological disorders.
Our work in Belgium focuses on multiple myeloma, lymphoma and chronic lymphocytic leukaemia (CLL), myeloid disorders, and myeloproliferative neoplasms (MPN).
Cardiovascular Disease
Every day, we are committed to developing innovative treatments for patients with cardiovascular diseases.
Our focus is both chronic and acute heart failure, with particular interest in patients with heart failure with preserved ejection fraction.
Medical Information and Services
Contact Information
Medical Information Contact Centre and reporting side effects or product quality complaints.
Visit our international website to report side effects or submit product quality complaints and questions about medical information in other countries.
Clinical studies are essential in developing new medicines. BMS Belgium is currently running 114 active clinical studies.
We want to ensure that patients receive the right treatment at the right time. That’s why in some cases, we provide patients with substantial unmet medical needs access to innovative treatments before they are commercially available.
